Dark

Check out our Dark Pool Levels

BLUE
bluebird bio, Inc. Common Stock
stock NASDAQ

Inactive

May 30, 2025

4.97USD0.000%(0.00)1,245,197

Pre-market

0.00USD-100.000%(-4.97)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 26, 2022

08:00AM EST Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces the appointment of Cintia Piccina as Chief Commercial Officer effective January 31, 2022. GlobeNewswire Inc

Jan 18, 2022

09:24AM EST FDA Pushes Review Period For Bluebird bio's Neurodegenerative Disease, Thalassemia Gene Therapies Benzinga

07:25AM EST The US Food and Drug Administration has extended the review period for the biologics licensing applications or BLA for lentiviral vector gene therapies - betibeglogene autotemcel (beti-cel) for -thalassemia and elivaldogene autotemcel (eli-cel) for cerebral adrenoleukodystrophy, bluebird bio Inc. (BLUE) said in a statement on Tuesday. RTTNews

07:14AM EST Bluebird Bio Announced FDA Has Extended the Review Period for the Biologics Licensing Applications for Its Lentiviral Vector Gene Therapies Benzinga

07:05AM EST Bluebird Bio : FDA Extends Review Period For BLA For Lentiviral Vector Gene Therapies RTTNews

07:00AM EST bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD) Business Wire

Jan 11, 2022

07:00AM EST bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference Business Wire

Jan 10, 2022

10:28AM EST State Street Corp. Reports In 13G Filing A 10.87% Stake In Bluebird Bio Benzinga

Jan 6, 2022

11:02AM EST Where bluebird bio Stands With Analysts Benzinga

10:19AM EST Morgan Stanley Maintains Underweight on bluebird bio, Lowers Price Target to $10 Benzinga

Jan 5, 2022

08:00AM EST bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 20, 2021

12:35PM EST Mid-Day Market Update: Crude Oil Drops Over 5%; Society Pass Shares Jump Benzinga

08:46AM EST bluebird bio, Inc. (BLUE) announced the FDA has placed its clinical program for lovotibeglogene autotemcel gene therapy for sickle cell disease on partial clinical hold for patients under the age of 18. The temporary suspension is related to an ongoing investigation by bluebird bio into an adolescent patient. The company noted that the patient is clinically well. RTTNews

08:19AM EST bluebird bio Shares To Resume Trade At 8:30 a.m. ET Benzinga

08:19AM EST bluebird bio Announces Partial Clinical Hold For Patients Under 18 In Sickle Cell Gene Therapy Clinical Program Benzinga

08:10AM EST Bluebird Bio Reports Partial Clinical Hold For Patients Under 18 In Sickle Cell Gene Therapy Clinical Program RTTNews

08:00AM EST bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program Business Wire

07:57AM EST Bluebird Bio Shares Halted; News Pending Benzinga

07:21AM EST Bluebird bio's Neurodegenerative Disease Gene Therapy Under Priority FDA Review, Despite Clinical Hold Benzinga

Dec 13, 2021

11:57AM EST bluebird bio Saturday Highlighted New Data That Further Showed beti-cel Is A Potentially Curative 1-Time Gene Therapy For B-Thalassemia Patients Who Require Regular Transfusions Through Achievement Of Durable T1, Normal, Near-Normal Adult Hb Levels Benzinga

Dec 12, 2021

05:08PM EST bluebird bio Announced New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Therapy Program To-Date Presented at ASH21, Published in New England Journal of Medicine Benzinga

04:56PM EST The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More Benzinga

Dec 6, 2021

08:35AM EST Blue Thunder Mining Inc. to Webcast Live at VirtualInvestorConferences.com PR Newswire

Dec 3, 2021

08:35AM EST Metals & Mining Live Virtual Investor Conference December 8th & 9th PR Newswire

Nov 22, 2021

11:35AM EST Bluebird Bio shares were trading higher after the company announced the FDA accepted the Biologics License Application for betibeglogene autotemcel for priority review. Benzinga

06:31AM EST bluebird bio Announces FDA Priority Review Of Biologics License Application For Beti-Cel Gene Therapy For Patients With -thalassemia Who Require Regular Red Blood Cell Transfusions Benzinga

Nov 8, 2021

09:06AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021 Benzinga

08:33AM EST Goldman Sachs Downgrades bluebird bio to Sell, Lowers Price Target to $10 Benzinga

08:29AM EST Barclays Maintains Equal-Weight on bluebird bio, Lowers Price Target to $13 Benzinga

06:15AM EST Morgan Stanley Downgrades bluebird bio to Underweight, Announces $11 Price Target Benzinga

Nov 5, 2021

09:39AM EDT bluebird bio Q3 EPS $(3.16) Down From $(2.94) YoY, Sales $22.68M Up From $19.27M YoY Benzinga

07:40AM EDT Bluebird Bio Q3 Total Revenues $22.7 Mln Vs. $19.3 Mln Prior Year RTTNews

07:05AM EDT bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress Business Wire

Oct 21, 2021

12:12PM EDT Bluebird Bio To Withdraw Marketing Of Skysona Gene Therapy In Europe Benzinga

12:12PM EDT bluebird bio To Withdraw Marketing Authorization For SKYSONA From EU And Withdraw Marketing Applicatino For SKYSONA From MHRA Benzinga

Oct 18, 2021

09:00AM EDT bluebird bio Sets Record Date and Distribution Date for Planned Business Separation Business Wire

08:36AM EDT Blue Thunder Mining Inc. to Webcast Live at VirtualInvestorConferences.com on PR Newswire

Oct 8, 2021

05:03PM EDT bluebird bio Highlights Filing By Its 2seventy Bio Related To Spin Off Benzinga

04:54PM EDT bluebird bio Provides Update on Upcoming Planned Business Separation Business Wire

Sep 22, 2021

12:34PM EDT What 6 Analyst Ratings Have To Say About bluebird bio Benzinga

07:59AM EDT Mizuho Maintains Buy on bluebird bio, Lowers Price Target to $23 Benzinga

07:45AM EDT The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs Benzinga

Sep 21, 2021

04:16PM EDT Bluebird Submits Biologics License Application To FDA For Betibeglogene Autotemcel Gene Therapy For Patients With -thalassemia Who Require Regular Red Blood Cell Transfusions Benzinga

Sep 13, 2021

08:00AM EDT 2seventy bio Announces Upcoming Investor Events Business Wire

Sep 8, 2021

09:01AM EDT bluebird bio Inc. (BLUE) said Wednesday that it has reached an agreement for a $75 million private placement of common stock and common stock equivalents with a healthcare investment fund selected as part of a competitive process. RTTNews

07:37AM EDT Bluebird Bio Says Secures $75 Mln In Private Placement Equity Financing RTTNews

07:36AM EDT bluebird bio Secures $75M in Private Placement Equity Financing Benzinga

07:32AM EDT The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod Benzinga

07:30AM EDT bluebird bio Secures $75 Million in Private Placement Equity Financing Business Wire

Sep 7, 2021

04:10PM EDT Bluebird Bio Announces Gina Consylman Appointed Chief Financial Officer And Marcela Maus Named To Bluebird Bio Board Of Directors Benzinga

04:05PM EDT bluebird bio Announces Key Management and Board Appointments and Upcoming Investor Events Business Wire

Sep 4, 2021

04:04PM EDT The Latest Barron's Picks And Pans Include General Electric, Netflix, Reddit And More Benzinga

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 13, 2021

10:50PM EDT BLUEBIRD BIO INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE Business Wire

Aug 11, 2021

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Aug 10, 2021

10:32AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2021 Benzinga

10:03AM EDT Canaccord Genuity Downgrades bluebird bio to Hold, Lowers Price Target to $20 Benzinga

07:56AM EDT Goldman Sachs Downgrades bluebird bio to Neutral, Lowers Price Target to $23 Benzinga

07:55AM EDT The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts Benzinga

07:31AM EDT Wells Fargo Downgrades bluebird bio to Equal-Weight, Lowers Price Target to $25 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

07:36AM EDT bluebird bio Q2 EPS $(3.43) Misses $(3.19) Estimate, Sales $7.47M Miss $19.68M Estimate Benzinga

07:26AM EDT Recap: bluebird bio Q2 Earnings Benzinga

07:14AM EDT Bluebird Bio Q2 Net Loss $241.7 Mln Vs. Net Loss $21.5 Mln Last Year RTTNews

07:00AM EDT bluebird bio Reports Second Quarter Financial Results and Provides Operational Update Business Wire

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 5, 2021

04:06PM EDT bluebird bio Announces Q2 Earnings Call and Upcoming Investor Events Business Wire

Aug 4, 2021

04:05PM EDT bluebird bio, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 28, 2021

08:17AM EDT Bluebird Bio And Resilience Announce Strategic Alliance To Develop Next Generation Cell Therapies; Bluebird To Receive $110M Upfront Payment Benzinga

08:00AM EDT Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies Business Wire

Jul 23, 2021

10:50PM EDT Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE PR Newswire

Jul 21, 2021

05:06AM EDT Bluebird Bio Received European Commission Approval for Skysona Benzinga

Jul 16, 2021

08:39AM EDT Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to $35 Benzinga

Jul 9, 2021

10:48AM EDT Bluebird Bio To Resume Zynteglo Gene Therapy Marketing In Europe After Positive Recommendation From PRAC Benzinga

07:32AM EDT bluebird bio Reports EMA's Pharmacovigilance Risk Assessment Committee Concluded Benefit-Risk Balance Of Medicinal Products Containing ZYNTEGLO Remains Favorable Benzinga

Jul 1, 2021

10:11AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 1, 2021 Benzinga

08:38AM EDT Berenberg Downgrades bluebird bio to Hold, Announces $35 Price Target Benzinga

Jun 11, 2021

10:50PM EDT BLUEBIRD BIO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of bluebird bio, Inc. - BLUE Business Wire

Jun 7, 2021

04:05PM EDT bluebird bio to Present at Goldman Sachs Global Healthcare Conference Business Wire

10:30AM EDT Bluebird Bio shares were trading higher after the company announced the lifting of FDA clinical holds for sickle cell disease and -Thalassemia Studies. Benzinga

09:55AM EDT Shares of bluebird bio Inc. (BLUE) are currently trading at $31.42, up 50 cents or 1.62%, with trading volume of over 698K versus an average volume of 1.40 million shares. The stock has been trading in the range of $24.24 - $72.30 for the past one year. RTTNews

09:53AM EDT FDA Gives Signal to Halted Bluebird Bio's Gene Therapy Trials In Sickle Cell Disease, Thalassemia Benzinga

09:04AM EDT bluebird bio, Inc. (BLUE) announced Monday that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the Phase 1/2 HGB-206 and Phase 3 HGB-210 studies of LentiGlobin for sickle cell disease (SCD) gene therapy (bb1111) for adult and pediatric patients with SCD. RTTNews

08:24AM EDT Bluebird Bio Says FDA Lifted Clinical Hold For Sickle Cell Disease And -Thalassemia Studies RTTNews

08:03AM EDT bluebird bio Announces Lifting Of FDA Clinical Hold For Sickle Cell Disease And -Thalassemia Studies Benzinga

Jun 2, 2021

04:05PM EDT bluebird bio, Inc. Reports Inducement Grants to CCO Tom Klima Under Nasdaq Listing Rule 5635(c)(4) Business Wire

May 21, 2021

08:01AM EDT bluebird bio Reports Positive CHMP Opinion For SKYSONA Gene Therapy For Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy Benzinga

May 13, 2021

08:29AM EDT Bluebird Bio To Present Data From Its Severe Genetic Disease And Oncology Portfolios During EHA2021 Virtual Congress Benzinga

May 5, 2021

04:54PM EDT bluebird bio Q1 EPS $(3.07) Up From $(3.64) YoY, Sales $12.79M Down From $21.86M YoY Benzinga

04:06PM EDT bluebird bio Reports First Quarter Financial Results and Highlights Operational Progress Business Wire

May 3, 2021

08:00AM EDT bluebird bio Announces May Investor Events Business Wire

Apr 20, 2021

07:49AM EDT bluebird bio Says Investigator Has Concluded Reported Case Of MDS In LentiGlobin Study Is Not MDS And Has Revised Diagnosis To Transfusion-Dependent Anemia Benzinga

07:30AM EDT bluebird bio Provides Update on Severe Genetic Disease Programs and Business Operations Business Wire

Apr 19, 2021

10:07AM EDT Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to $36 Benzinga

Apr 14, 2021

07:11AM EDT bluebird bio, PsiOxus Highlight Presentation Of Novel Data Combining T-SIGn Platform With CAR-T Therapy To Clear Primary Tumors, Metastases Benzinga

Mar 29, 2021

08:05AM EDT 10 Biggest Price Target Changes For Monday Benzinga

08:01AM EDT Abecma has become the first cell-based gene therapy approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma, an uncommon type of cancer. RTTNews

06:53AM EDT SVB Leerink Maintains Outperform on bluebird bio, Raises Price Target to $72 Benzinga

Mar 27, 2021

01:01PM EDT The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week Benzinga

Mar 15, 2021

05:40AM EDT bluebird bio Announced Long-Term Data for elivaldogene autotemcel (eli-cel, Lenti-D) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) Show 90% of Evaluable Patients (27/30) Alive and Free of Major Functional Disabilities at Two Years Follow-up in Phase 2/3 Starbeam Study Benzinga

Mar 10, 2021

11:13AM EST Mizuho Upgrades bluebird bio to Buy, Raises Price Target to $69 Benzinga

10:55AM EST UPDATE: Mizuho, On bluebird bio Upgrade, Cites Co. News From Wednesday Morning On Recent Case Of Acute Myeloid Leukemia In Co.'s Sickle Cell Disease Program Benzinga

08:29AM EST Bluebird Bio Says Lentiviral Vector Not the Cause Of Blood Cancer Reported In Sickle Cell Study Benzinga

07:26AM EST The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link Benzinga

07:24AM EST Bluebird Bio Provides Updated Findings From Reported Case Of Acute Myeloid Leukemia In LentiGlobin RTTNews

07:15AM EST UPDATE: bluebird bio Says Has Initiated Process With Regulators To Resume Clinical Studies Benzinga

07:14AM EST bluebird bio Provides Findings From Reported Case of Acute Myeloid Leukemia In LentiGlobin In Sickle Cell Disease; Says 'Analyses demonstrate lentiviral vector BB305 unlikely to be the cause of AML in clinical study of LentiGlobin for SCD' Benzinga

07:00AM EST bluebird bio Provides Updated Findings from Reported Case of Acute Myeloid Leukemia (AML) in LentiGlobin for Sickle Cell Disease (SCD) Gene Therapy Program Business Wire

Mar 2, 2021

12:30PM EST Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline GlobeNewswire Inc

11:38AM EST BLUEBIRD BIO, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler GlobeNewswire Inc

07:53AM EST Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to $45 Benzinga

Mar 1, 2021

11:55PM EST Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - BLUE PR Newswire

12:00PM EST Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

09:32AM EST BLUE SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds GlobeNewswire Inc

Feb 28, 2021

11:38AM EST Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates Benzinga

Feb 26, 2021

08:02AM EST bluebird bio To Present At Cawen Healthcare Conference March 3 At 2:40 p.m. ET Benzinga

08:00AM EST bluebird bio to Present at Cowen Health Care Conference Business Wire

Feb 25, 2021

03:24PM EST '$BLUE disclosed new info during presentation at Leerink conference at noon today, suggesting Lentiglobin not the cause of two new cancer cases...' -Tweet From STAT News' Adam Feuerstein Benzinga

11:00AM EST The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion. GlobeNewswire Inc

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

Feb 24, 2021

05:35PM EST Bluebird Bio Announces That The Results From Its Pivotal Phase 2 KarMMa Study Evaluating The Efficacy And Safety Of Its Co.'s And Bristol Myers Squibb In The New England Journal Of Medicine Benzinga

01:19PM EST BLUE SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds GlobeNewswire Inc

10:24AM EST Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of bluebird bio, Inc. (NASDAQ: BLUE) from May 11, 2020 through November 4, 2020, inclusive (the Class Period). The lawsuit seeks to recover damages for bluebird bio, Inc. investors under the federal securities laws. GlobeNewswire Inc

07:30AM EST The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO Benzinga

Feb 23, 2021

04:21PM EST bluebird bio Q4 EPS $(3.01) Up From $(4.04) YoY, Sales $10.71M Up From $10.00M YoY Benzinga

04:06PM EST bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational Progress Business Wire

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

Feb 22, 2021

04:05PM EST bluebird bio to Present at Leerink Global Healthcare Conference Business Wire

Feb 19, 2021

09:01AM EST LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against bluebird bio, Inc. PR Newswire

08:01AM EST Against bluebird bio, Inc. (NASDAQ: BLUE); Lead Plaintiff Deadline is April 13, 2021 PR Newswire

12:05AM EST Investment in bluebird bio, Inc. of Class Action Lawsuit and Upcoming Deadline - BLUE PR Newswire

Feb 18, 2021

11:49AM EST Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm PR Newswire

11:03AM EST BLUE SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds GlobeNewswire Inc

10:00AM EST BLUE Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies GlobeNewswire Inc

Feb 17, 2021

11:27PM EST BLUE INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class PR Newswire

08:00PM EST Investors with Large Losses to Secure Counsel Before Important Deadline - BLUE PR Newswire

10:12AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2021 Benzinga

08:36AM EST 10 Biggest Price Target Changes For Wednesday Benzinga

07:27AM EST The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal Benzinga

06:32AM EST JP Morgan Downgrades bluebird bio to Neutral, Lowers Price Target to $39 Benzinga

Feb 16, 2021

03:04PM EST Mid-Afternoon Market Update: Crude Oil Rise; Energy Shares Continue To Climb Benzinga

02:55PM EST BLUEBIRD BIO, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler GlobeNewswire Inc

01:02PM EST Mid-Day Market Update: Gold Slides Further, GW Pharma Reports Topline Growth Benzinga

12:46PM EST 43 Stocks Moving In Tuesday's Mid-Day Session Benzinga

10:55AM EST Mid-Morning Market Update: Gold Down 1.6%; Socket Mobile Shares Surge Higher Benzinga

10:00AM EST BLUE Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies bluebird bio, PR Newswire

09:59AM EST Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, announces that a lawsuit for violation of the federal securities laws has been filed against bluebird bio, Inc. (NASDAQ: BLUE) and certain of its executives. GlobeNewswire Inc

08:00AM EST Portnoy Law: Lawsuit Filed On Behalf of Bluebird Bio Inc. Investors GlobeNewswire Inc

07:09AM EST bluebird bio Shares to Resume Trade At 7:30 a.m. ET Benzinga

07:02AM EST bluebird bio Announces Temporary Suspension On Phase 1/2 And Phase 3 Studies Of LentiGlobin Gene Therapy For Sickle Cell Disease Following Report Received That A Patient Who Was Treated More Than Five Years Ago In Group A Of HGB-206 Was Diagnosed With AML Benzinga

07:00AM EST bluebird bio Announces Temporary Suspension on Phase 1/2 and Phase 3 Studies of LentiGlobin Gene Therapy for Sickle Cell Disease (bb1111) Business Wire

Feb 15, 2021

04:05PM EST Gainey McKenna & Egleston Announces A Class Action Lawsuit Has GlobeNewswire Inc

11:22AM EST Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of bluebird bio, Inc. (bluebird or the Company) (NASDAQ: BLUE) to determine whether the Company engaged in securities fraud or other unlawful business practices. GlobeNewswire Inc

Feb 12, 2021

05:54PM EST Pomerantz Law Firm Announces the Filing of a Class Action against bluebird bio, PR Newswire

Jan 12, 2021

10:58AM EST Cramer Gives His Opinion On Uber, Starbucks And More Benzinga

Jan 11, 2021

10:04AM EST Bluebird Bio shares were trading higher after the company announced it would spin off its oncology business into a separate publicly traded company. Benzinga

08:14AM EST Bluebird Bio Anticipates That Cash, Cash Equivalents, Marketable Securities Were About $1.3B As Of December 31, 2020 Benzinga

06:44AM EST bluebird bio, Inc. (BLUE) announced its intent to separate its severe genetic disease and oncology businesses into independent publicly traded companies. bluebird bio, Inc. will retain focus on severe genetic disease and will launch its oncology business as a new entity. RTTNews

06:38AM EST Bluebird Bio To Retain Focus On Severe Genetic Disease And To Launch Its Oncology Business As New Entity RTTNews

06:35AM EST Bluebird Bio to Separate its Oncology Business Into a Separate Publicly Traded Company Benzinga

06:30AM EST bluebird bio to Separate Oncology Business into Independent Company Business Wire

Dec 7, 2020

04:33PM EST bluebird bio Highlights Presentation Of Data From Phase 1/2 HGB-206 Study Of LentiGlobin Gene Therapy At American Society Of Hematology Annual Meeting Benzinga

Dec 6, 2020

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Dec 4, 2020

08:07AM EST Magenta Therapeutics And Bluebird Bio Announce A Phase 2 Trial Collaboration To Evaluate Magenta's MGTA-145 RTTNews

08:05AM EST Magenta Therapeutics And bluebird bio Announce A Phase 2 Clinical Trial Collaboration To Evaluate Magenta's MGTA-145 For Mobilizing And Collecting Stem Cells In Adults And Adolescents With Sickle Cell Disease Benzinga

Nov 30, 2020

09:57PM EST Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. (bluebird or the Company) (NASDAQ: BLUE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Nov 24, 2020

08:00AM EST bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting Business Wire

Nov 21, 2020

11:12PM EST Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. (bluebird or the Company) (NASDAQ: BLUE). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Nov 11, 2020

10:56AM EST Berenberg Initiates Coverage On bluebird bio with Buy Rating, Announces Price Target of $64 Benzinga

07:50AM EST Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to $50 Benzinga

Nov 10, 2020

09:29PM EST SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of PR Newswire

08:00AM EST bluebird bio Announces November Investor Events Business Wire

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 5, 2020

12:15PM EST Mid-Day Market Update: Silver Surges 5%; Hanesbrands Shares Plunge Benzinga

11:42AM EST Yahoo Finance Trending Stocks For Thursday, Nov. 5, 2020: QCOM, XPEV, UPWK, ACB, BIIB, GM, KXIN, FROG, HOFV, BLUE, TEVA, LIN, TLRY, HBI, PLTR, OPTI, CLVS, ZNGA, APHA, BABA, ALTM, GOLD, MFA, IIVI, PING, ACB, QRVO, ESALY Benzinga

11:23AM EST Why Bluebird Bio's Stock Is Trading Lower Today Benzinga

10:28AM EST Benzinga's Top Upgrades, Downgrades For November 5, 2020 Benzinga

10:24AM EST Mid-Morning Market Update: Markets Open Higher; General Motors Profit Tops Estimates Benzinga

09:33AM EST Piper Sandler Maintains Neutral on bluebird bio, Lowers Price Target to $55 Benzinga

09:10AM EST ROCE Insights For bluebird bio Benzinga

08:15AM EST 10 Biggest Price Target Changes For Thursday Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

07:28AM EST B of A Securities Maintains Buy on bluebird bio, Lowers Price Target to $81 Benzinga

06:30AM EST SVB Leerink Maintains Outperform on bluebird bio, Lowers Price Target to $99 Benzinga

05:41AM EST BMO Capital Downgrades bluebird bio to Market Perform, Announces $56 Price Target Benzinga

Nov 4, 2020

10:33PM EST Bluebird Bio Q3 Loss Narrows; Adjusts LentiGlobin BLA RTTNews

05:31PM EST Bluebird Bio Q3 Loss/Shr $2.94; Adjusts LentiGlobin BLA Submission Timing To Late 2022 RTTNews

04:29PM EST bluebird bio Q3 EPS $(2.94) Up From $(3.73) YoY, Sales $19.27M Up From $8.91M YoY Benzinga

04:06PM EST bluebird bio Reports Third Quarter 2020 Financial Results and Highlights Operational Progress Business Wire

Oct 20, 2020

11:56AM EDT Why This Bluebird Bio Analyst Sees Over 125% Upside Ahead Benzinga

06:06AM EDT Mizuho Initiates Coverage On bluebird bio with Buy Rating, Announces Price Target of $123 Benzinga

Oct 2, 2020

05:45AM EDT Bluebird Bio: European Medicines Agency To Review Eli-cel RTTNews

05:32AM EDT Bluebird Bio: EMA Accepts MAA For Investigational Elivaldogene Autotemcel Gene Therapy RTTNews

05:26AM EDT bluebird bio Announced EMAg Acceptance of Marketing Authorization Application for elivaldogene autotemcel (eli-cel, Lenti-D) Gene Therapy for Cerebral Adrenoleukodystrophy Benzinga

Sep 28, 2020

08:00AM EDT bluebird bio to Present at Jefferies Cell Therapy Virtual Summit Business Wire

Sep 22, 2020

06:59AM EDT FDA Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel Benzinga

Sep 2, 2020

08:00AM EDT bluebird bio Announces September Investor Events Business Wire

Aug 17, 2020

07:06AM EDT bluebird bio To Present New Data From Clinical Studies Of Elivaldogene Autotemcel Gene Therapy For Cerebral Adrenoleukodystrophy At Virtual Edition Of 46th EBMT Annual Meeting Aug. 91-Sept. 1 Benzinga

Aug 11, 2020

07:05AM EDT Bluebird Bio Appoints Denice Torres To Board RTTNews

07:01AM EDT bluebird bio Appoints Denice Torres to Board of Directors Business Wire

Aug 10, 2020

08:50AM EDT Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to $68 Benzinga

Aug 6, 2020

11:42AM EDT Why Bluebird Bio's Stock Is Trading Higher Today Benzinga

11:38AM EDT BMO Capital Maintains Outperform on bluebird bio, Lowers Price Target to $108 Benzinga

08:14AM EDT Wedbush Maintains Outperform on bluebird bio, Lowers Price Target to $81 Benzinga

Aug 5, 2020

04:53PM EDT bluebird bio Q2 EPS $(0.36) Up From $(3.55) YoY, Sales $198.89M Up From $13.30M YoY Benzinga

04:10PM EDT bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress Business Wire

Jul 31, 2020

08:00AM EDT bluebird bio Announces August Investor Event Business Wire

Jul 29, 2020

04:28PM EDT Bristol Myers Squibb And bluebird bio Announce Submission of Biologics License Application To FDA For Idecabtagene Vicleucel For Adults With Relapsed And Refractory Multiple Myeloma Benzinga

Jul 22, 2020

10:00AM EDT C-Suite At The Open: Robert Cinits, President & CEO, Blue Thunder Mining Inc. PR Newswire

Jul 13, 2020

12:08PM EDT B of A Securities Maintains Buy on bluebird bio, Lowers Price Target to $100 Benzinga

Share